- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Every year, innovators rush into GLP studies before they're truly ready
.png)
If you vomit within three hours of taking levonorgestrel emergency contraception, contact your GP, pharmacist, or sexual health clinic immediately, as you may need to take another dose
Similarly, Pieczykolan et al
Peptide therapy helps your body keep up with what you ask it to do
60+ deals Weight Loss in Monroe, NC 60+ Deals available CosmeticRX Semaglutide or Tirzepatide Weight Loss Program with Consultation 4.1(4,377) -80% 1stRX Semaglutide and Tirzepatide Weight Loss Programs with Consultation 4.1(80) -40% FancyMeds Semaglutide or Tirzepatide Weight Loss Program with Consultation 3.7(949) -72% LeanerRx Semaglutide or Tirzepatide Weight Management Program with Consultation 4.3(835) -60% Juiced